The 2026 competition invites the protein-design community to engineer a nanobody that activates NK2R on its own, without relying on a natural ligand. Binding alone will not suffice: a successful design must shift the receptor into its active state and produce measurable agonist activity.

This international symposium commemorates three decades of breakthroughs in epigenetics — from the landmark discovery of GCN5/HAT activity to the translation of chromatin mechanisms into therapeutic innovation.